Delayed Intensification Including Venetoclax and Bortezomib Prolongs Survival in Very High Risk Acute Lymphoblastic Leukaemia
Jasmeet Sidhu(Tata Medical Center), Shekhar Krishnan(University of Manchester), Debjani Ghosh(Tata Medical Center), Fabio D. Steffen(University Children's Hospital Zurich), Niharendu Ghara(Tata Medical Center), Manash Pratim Gogoi(Tata Medical Center), Tanima Dey, Vaskar Saha(University of Manchester), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Subhajit Kundu, Debdutta Ganguli, Arijit Chakraborty(Harvard University), Parag Das, Beat Bornhäuser(University Children's Hospital Zurich), Abhirupa Kar, Sangramjit Basu
Cited by 1
Related Papers
Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
|Journal of Clinical Investigation|2010|311
<i>IKZF1</i><sup>plus</sup>Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
|Journal of Clinical Oncology|2018|304
Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2012|296